Navigation Links
China-Biotics, Inc. Reports Third Quarter 2009 Financial Results
Date:2/16/2009

SHANGHAI, Feb. 16 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced its financial results for the third quarter of its 2009 fiscal year, ended December 31, 2008.

    Third Quarter 2009 Highlights

    -- Net sales increased 32.5% year-over-year to $15.8 million
    -- Gross profit increased 28.3% year-over-year to $11.2 million, with
       gross margin of 71%
    -- Net income increased 40.2% year-over-year $5.7 million
    -- Excluding a $1.4 million gain related to the change in fair value of
       convertible notes, net income increased 5.4% year-over-year to $4.3
       million
    -- Diluted earnings per share were $0.22, compared to $0.23 the prior year
    -- Signed agreements with six additional business customers to supply
       probiotics as bulk additives for dairy products

Third Quarter 2009 Results

During the third quarter of the 2009 fiscal year, net sales increased 32.5% to $15.8 million from $11.9 million the prior year. Growth in revenues stemmed from increased sales volume of new products and changes in the Company's sales mix, as China-Biotics reaped the benefits of ongoing, targeted price increases on selected products. Compared to the prior year, sales also benefitted from an increase in the number of the Company's Shining retail outlets to 107 from 27 in the fiscal third quarter a year ago. Newer products, including Shining Essence Stomach Protection Capsules and Shining Probiotics Protein Powder, accounted for 19.6% of total sales during the quarter, up from a combined 13.1% of sales a year ago. Sales of bulk additives to commercial customers totaled $1.1 million, or 7.1% of sales, during the third quarter of 2009, up from $0.1 million, or 1.2% of sales, during the third quarter of 2008, as the Company continued to generate orders from agreements with new customers and expand production to fill orders from existing customers.

"We again achieved solid sales and profit growth during the third quarter, as our bulk additives and retail expansion strategies continued to generate strong results," said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. "During the quarter, we continued to balance current demand against future sales growth, adjusting our product pricing to maximize production capacity. We focused on fine-tuning our Shining retail outlet operations, closing one unproductive location and two sites where the Shanghai government is engaged in urban redevelopment. On the bulk additives side of the business, we added six additional food customers during the quarter, and we remain in negotiations with more than 100 potential business clients."

Gross profit increased 28.3% to $11.2 million from $8.7 million in the same quarter the prior year. Gross margin was 71.0%, compared to 73.3% a year ago. This was primarily caused by an increase in the cost of packaging materials, including pulp and paper costs.

Selling expenses increased to $3.3 million, or 21.1% of sales, from $1.8 million, or 14.7% of sales, a year ago, as a result of the increased number of retail outlets. General and administrative expenses increased to $1.4 million, or 8.6% of sales, from $1.3 million, or 10.6% of sales, in the third quarter the prior year. The slight increase was primarily related to $0.1 million of additional research costs to develop and launch new products.

Operating expenses during the quarter were $4.7 million, or 29.6% of sales, compared to $3.0 million, or 25.2% of sales, a year ago.

Operating income for the quarter was $6.5 million, an increase of 14.1% from $5.7 million a year ago.

Other income of $1.4 million in the third quarter of 2009 consisted of a book gain related to the change in the fair value of the $25 million in convertible notes the Company issued in December 2007.

Net income during the third quarter was $5.7 million. Excluding the $1.4 million gain on the revaluation of the convertible notes, net income was $4.3 million, up 5.4% from $4.0 million during the same quarter the prior year.

Diluted earnings per share were $0.22, compared with $0.23 per diluted share in the third quarter of fiscal 2008. The calculation of diluted earnings per share for the third quarter of 2009 assumes full conversion of the convertible notes and thus excludes the gain from the change in fair value of the notes.

Nine-Month Results

Net sales for the first nine months of the 2009 fiscal year were $38.7 million, up 32.2% from $29.3 million in the same period the prior year. Gross profit was $27.4 million, or 70.8% of sales, up 28.9% from gross profit of $21.2 million, or 72.0% of sales, in the first nine months of fiscal 2008. Operating income was $14.6 million, or 37.9% of sales, an increase of 8.9% from $13.4 million, or 45.9% of sales, the prior year. Net income for the first nine months of fiscal 2009 was $13.4 million, or $0.59 per diluted share, up from $9.6 million, or $0.55 per diluted share, in the same period of fiscal 2008. Excluding the $2.1 million gain on the revaluation of the convertible notes, net income was $11.3 million, up 18.3% from $9.6 million during the same period the prior year.

Financial Condition

As of December 31, 2008, the Company had cash and cash equivalents of $66.4 million and working capital of $50.8 million. Days' sales outstanding for the third quarter of the 2009 fiscal year was 72 days, compared to 85 days in the second quarter. At December 31, 2008, the Company had stockholders' equity of $58.9 million.

In the first nine months of fiscal 2009, China-Biotics generated $17.1 million in cash flow from operations and recorded $15.1 million in capital expenditures, mainly related to the construction of its new $27.5 million manufacturing facility. The Company expects to spend another $11 million in capital expenditures on the new facility during the fourth quarter of fiscal 2009. The remaining $2.5 million is expected to be paid during fiscal 2010. The Company believes its current cash balance, combined with cash flow from operations, will be sufficient to fund its planned expenditures during the next 12 months.

Business Outlook

The Company's new bulk additives production facility is expected to begin trial production in April 2009. To date, China-Biotics has signed agreements with eleven business customers to supply those customers with bulk probiotics in powder form that can be added to products such as milk, ice cream, yogurt, beverages, baked goods and nutritional supplements.

Management continues to balance current capacity against future sales growth and expects to resume the expansion of its Shining retail outlets at a moderate pace. This should enable the Company to concentrate on the completion of the new manufacturing facility and the addition of new bulk additives customers to fill production capacity once the facility begins operations. The Company remains confident in its plan to open a total of 300 Shining outlets during the 2010 fiscal year.

"We continue to make progress in both the retail and commercial aspects of our business, with 107 Shining retail centers and eleven bulk additives customers. We look forward to finishing the 2009 fiscal year in strong fashion, as the third and fourth fiscal quarter are typically our seasonally strongest, producing 60% of retail sales," Mr. Song said. "We also resumed construction of our new manufacturing facility following the Chinese New Year holiday, and we remain on track to complete the project in April."

Recent Events

Also in January, the Company announced the State Food and Drug Administration has approved manufacturing certificates for the production of several new products, including Synbiotics Capsules, Probiotics Gegen Capsules, Probiotics Tremella Polysaccharide Capsules and Probiotics Chewable Tablets. The new probiotics-based products were developed during an eight-month process and are currently in production at the Company's existing manufacturing facility. The products are intended to offer several different health solutions to consumers, enhancing adolescents' immune systems and gastrointestinal ("GI") health, improving women's GI health, relieving menopausal symptoms, enhancing the GI health and immune systems of seniors, reducing the creation of enteric pathogenic bacteria and increasing consumers' energy levels.

Conference Call

The company will host a conference call at 10:00 a.m. EST on, Tuesday, February 17, 2009, to discuss its financial results for the fiscal third quarter ended December 31, 2008. To participate in the event by telephone, please dial +1-888-241-0558 five to 10 minutes prior to the start time (to allow time for registration) and reference passcode 85103904. International callers should dial +1-647-427-3417. The conference call will be webcast live over the Internet and can be accessed by all interested parties at the Company's Web site, http://www.chn-biotics.com . To listen to the call, please visit the site at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. For those unable to participate during the live webcast, it will be archived using the same link for 90 days. A digital replay of the call will also be available on Tuesday, February 17, at approximately 12:00 p.m. EST through Tuesday, February 24, at midnight EST. Dial +1-888-562-2825 and enter the conference ID number 85103904. International callers should dial +1-402-220-7740 and enter the same conference ID number.

Use of Non-GAAP Financial Information

GAAP results for the third quarter and nine months ended December 31, 2008, include a non-cash gain related to the change in fair value of the Company's convertible notes. To supplement the Company's condensed consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP financial information excluding the impact of this item, which is non-GAAP net income, in this release. The Company's management believes that this non-GAAP measure provides investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of adjustments to GAAP results appears in the table accompanying this press release. This additional non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies.

About China-Biotics, Inc.

China-Biotics, Inc. ("China-Biotics," "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the "Shining" brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit http://www.chn-biotics.com .

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

                         - FINANCIAL TABLES FOLLOW -



                      CHINA-BIOTICS, INC. AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                        (Amounts expressed in U.S. Dollars)

                                                  December 31,      March 31,
                                                      2008            2008
    ASSETS
    Current assets
      Cash and cash equivalents                 $  66,424,118    $ 64,310,448
      Accounts receivable                          14,319,107      13,214,531
    Other receivables                                 246,515         238,835
      Inventories                                   1,265,539         408,358
      Prepayment                                    1,634,695       1,806,605
    Total current assets                        $  83,889,974    $ 79,978,777
    Property, plant and equipment
     and land use right                            31,621,007      13,812,749
    Total assets                                $ 115,510,981    $ 93,791,526

    LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities
      Accounts payable                           $  4,799,522    $  2,786,180
      Tax payables                                 25,545,893      22,317,982
      Other payables and accruals                   2,738,682       1,792,156
    Total current liabilities                    $ 33,084,097    $ 26,896,318
    Non-current liabilities
      Convertible note, with embedded
       derivatives of $3,679,000, net of
       discount of $6,688,163 as of
       December 31, 2008                         $ 21,990,837    $ 22,197,635
        Interest payable                            1,058,499         302,306
        Deferred tax liabilities                      500,167              --

    Total non-current liabilities                $ 23,549,503    $ 22,499,941
    Commitments and contingencies
    Stockholders' equity:
      Common stock (par value of $0.0001,
       100,000,000 shares authorized,
       41,461,004 shares issued and
       outstanding as of December 31, 2008)      $      4,146    $      4,146
      Additional paid-in capital                    7,863,031       7,863,031
      Retained earnings                            43,204,901      29,827,144
        Treasury stock at cost
         (24,381,004 shares)                           (2,438)         (2,438)
      Accumulated other comprehensive income        4,781,947       3,677,590
      Capital and statutory reserves                3,025,794       3,025,794

    Total stockholders' equity                   $ 58,877,381    $ 44,395,267
    Total liabilities and stockholders'
     equity                                      $115,510,981    $ 93,791,526



                      CHINA-BIOTICS, INC. AND SUBSIDIARIES
            UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                       (Amounts expressed in U.S. Dollars)

                              Three months ended         Nine months ended
                                  December 31,              December 31,
                               2008         2007          2008        2007

    Net sales             $15,810,111  $11,931,306    $38,676,017  $29,266,801

    Cost of sales          (4,583,371)  (3,183,056)   (11,304,893)  (8,039,651)

    Gross profit          $11,226,740   $8,748,250    $27,371,124  $21,227,150
    Operating expenses:

    Selling expenses      $(3,330,668) $(1,752,637)   $(8,514,090) $(4,630,916)
    General and
     administrative
     expenses              (1,353,561)  (1,258,927)    (4,218,494)  (3,155,544)

    Total operating
     expenses             $(4,684,229) $(3,011,564)  $(12,732,584) $(7,786,460)

    Income from
     operations            $6,542,511   $5,736,686    $14,638,540  $13,440,690
    Other income and
     expenses:
    Changes in the
     fair value of
     embedded
     derivatives          $1,408,000   $       --     $2,073,000   $       --

    Other income              60,442      118,064      1,923,430      190,006

    Other expenses           (42,718)    (384,212)      (260,297)    (404,147)

    Total other income
     (expenses)           $1,425,724    $(266,148)    $3,736,133   $ (214,141)

    Income before taxes   $7,968,235   $5,470,538    $18,374,673  $13,226,549

    Provision for
     income taxes         (2,299,348)  (1,426,789)    (4,996,916)  (3,672,434)

    Net income            $5,668,887   $4,043,749    $13,377,757   $9,554,115

    Earnings per share:
    Basic                   $   0.33      $  0.24        $  0.78    $    0.56
    Diluted                 $   0.22      $  0.23        $  0.59    $    0.55

    Weighted average shares
     outstanding
      Basic               17,080,000   17,080,000     17,080,000   17,080,000

      Diluted             19,163,333   17,555,543     19,163,333   17,239,090



                      CHINA-BIOTICS, INC. AND SUBSIDIARIES
             UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW
                        (Amounts expressed in U.S. Dollars)

                                                        Nine months ended
                                                            December 31,
                                                         2008          2007
    CASH FLOW FROM OPERATING ACTIVITIES
    Net income                                      $13,377,757    $9,554,115
    Adjustment for:
    Changes in the fair value of embedded
     derivatives                                     (2,073,000)           --
    Loss on disposal of plant and equipment              30,022            --
    Depreciation                                      1,298,953       625,357
    Change in deferred tax                              500,000            --
    (Increase)/Decrease in accounts receivable         (792,146)    2,360,417
    (Increase)/Decrease in inventories                 (841,095)     (526,663)
    (Increase)/Decrease in prepayments                  216,069    (1,596,989)
    Increase/(Decrease) in accounts payable           1,926,337       812,003
    Increase/(Decrease) in income tax, surcharge
     tax and dividends withholding tax                2,486,572     1,754,188
    Increase/(Decrease) in other payables and
     accruals, and value added tax payable              957,512       329,998
    NET CASH PROVIDED BY OPERATING ACTIVITIES       $17,086,981   $13,312,426
    CASH FLOWS USED IN INVESTING ACTIVITIES
    Purchases of fixed assets                      $(15,144,845)  $(8,398,701)
    Capital expenditure                                (808,219)           --
    NET CASH USED IN INVESTING ACTIVITIES          $(15,953,064)  $(8,398,701)
    CASH FLOWS PROVIDED BY FINANCING ACTIVITIES
    Issue of convertible notes                               --    25,000,000
    Effect of exchange rate changes on cash            $979,753    $2,175,977
    NET INCREASE IN CASH AND CASH EQUIVALENTS
     BALANCES                                        $2,113,670   $32,089,702
    CASH AND CASH EQUIVALENTS BALANCES AT
     BEGINNING OF PERIOD                             64,310,448    26,992,025
    CASH AND CASH EQUIVALENTS BALANCES AT END OF
     PERIOD                                         $66,424,118   $59,081,727




                     CHINA-BIOTICS, INC. AND SUBSIDIARIES
                  RECONCILIATION OF NON-GAAP FINANCIAL DATA

                                                      Three months ended
                                                          December 31,
                                                      2008          2007
    Net Income                                     4,260,887      4,043,749
    Adjustments
    Non-cash surplus arising from change in
     the fair value of embedded derivatives        1,408,000             --
    Amount per consolidated statement of
     operations                                    5,668,887      4,043,749


                                                       Nine months ended
                                                          December 31,
                                                      2008           2007
    Net Income                                    11,304,757      9,554,115
    Adjustments
    Non-cash surplus arising from change in
     the fair value
     of embedded derivatives                       2,073,000             --
    Amount per consolidated statement of
     operations                                   13,377,757      9,554,115


    For more information, please contact:

     CCG Investor Relations
     Crocker Coulson, President
     Tel:   +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com
     Web:  http://www.ccgirasia.com

'/>"/>
SOURCE China-Biotics, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. China-Biotics, Inc. Announces Conference Call to Discuss Third Quarter 2009 Financial Results
2. China-Biotics, Inc. Signs Agreements With Four Additional Food Manufacturers
3. China-Biotics, Inc. Announces Conference Call to Discuss Second Quarter 2009 Financial Results
4. China-Biotics, Inc. Sees No Impact on Its Business From Dairy Products Safety Concerns
5. China-Biotics, Inc. Expands Retail Network to 60 Shining Retail Centers
6. Environmental Tectonics Corporation Reports Receipt of Non-Compliance Notice from NYSE Alternext US LLC
7. Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results
8. Winner Medical Reports First Quarter Fiscal 2009 Results
9. Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results
10. TV News Coverage Reports on InnerCools CoolBlue System Treatment of Cardiac Shock Patient Following Childbirth at Rush Hospital, Chicago
11. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in ... America . ... ... ... ...
Breaking Medicine Technology: